retatrutide patent owner Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation retatrutide patent owner Pharmaceutical Patent

Its just very challenging right now for payers to be able to afford covering these medications for everyone who could benefit. The obesity rate in the United States among adults was 40% in August 2023, according to the Centers for Disease Control and Prevention

GLP-1s are a marathon

Evidence: The SCALE clinical programme demonstrated significant benefits, with participants achieving an average weight loss of approximately 8 per cent of baseline body weight at 56 weeks, compared with around 3 per cent in those who received lifestyle intervention alone

For Type 1 diabetes patients, GLP-1 drugs cannot replace insulin because these patients lack the beta cells needed for GLP-1-stimulated insulin secretion